Onconetix Executes 1-for-5 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Onconetix's Board approved a 1-for-5 reverse stock split effective March 25, 2026.
- The split reduces outstanding shares from ~3.6 million to ~0.7 million.
- Approval came after stockholder vote on February 3, 2026, authorizing splits between 1-for-2 and 1-for-50.
- Move intended to maintain compliance with Nasdaq's $1 minimum bid price requirement.
- Common stock will continue trading under symbol 'ONCO' with new CUSIP number 68237Q 302.
The big picture
Onconetix's reverse stock split reflects a common strategy among small-cap biotechs facing Nasdaq delisting threats. The move comes amid broader industry consolidation, with Onconetix simultaneously pursuing its Realbotix acquisition. The split's success will hinge on whether it stabilizes the stock price while maintaining investor confidence during integration.
What we're watching
- Compliance Sustainability
- Whether the reverse split will maintain Nasdaq listing eligibility long-term.
- Market Reaction
- How investors respond to the reduced share count and potential liquidity impact.
- Integration Challenges
- The pace at which Onconetix can integrate Realbotix operations post-acquisition.
Related topics